Diversity in a simple co-crystal: racemic and kryptoracemic behaviourElectronic supplementary information (ESI) available: Experimental procedures and analytical data. CCDC 1480079-1480081. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c6cc04148e

The crystal structure containing (±)-3-methyl-2-phenylbutyramide with salicylic acid is the first example of a kryptoracemate co-crystal. It exhibits the first temperature mediated reversible single-crystal to single-crystal transition between two kryptoracemate forms, in addition to crystallising i...

Full description

Saved in:
Bibliographic Details
Main Authors Rao Khandavilli, U. B, Lusi, Matteo, Bhogala, Balakrishna R, Maguire, Anita R, Stein, Matthias, Lawrence, Simon E
Format Journal Article
Published 23.06.2016
Online AccessGet full text

Cover

Loading…
More Information
Summary:The crystal structure containing (±)-3-methyl-2-phenylbutyramide with salicylic acid is the first example of a kryptoracemate co-crystal. It exhibits the first temperature mediated reversible single-crystal to single-crystal transition between two kryptoracemate forms, in addition to crystallising in another, racemic, form. Theoretical calculations and structural analysis reveal that there are only small differences in both energy and packing arrangements between the three forms. These results suggest that co-crystals can be an opportunity to investigate kryptoracemate behaviour. The first kryptoracemate co-crystal displays structural diversity and a reversible single-crystal to single-crystal transition between two kryptoracemate forms.
Bibliography:Electronic supplementary information (ESI) available: Experimental procedures and analytical data. CCDC
1480079-1480081
For ESI and crystallographic data in CIF or other electronic format see DOI
10.1039/c6cc04148e
ISSN:1359-7345
1364-548X
DOI:10.1039/c6cc04148e